Next Article in Journal
Anti-Inflammatory Influences of Cystic Fibrosis Transmembrane Conductance Regulator Drugs on Lung Inflammation in Cystic Fibrosis
Next Article in Special Issue
GPR21 Inhibition Increases Glucose-Uptake in HepG2 Cells
Previous Article in Journal
ERα36–GPER1 Collaboration Inhibits TLR4/NFκB-Induced Pro-Inflammatory Activity in Breast Cancer Cells
Previous Article in Special Issue
Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity

Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection

Department of Physiology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland
Author to whom correspondence should be addressed.
Academic Editors: Elisa Benetti and Gemma K. Kinsella
Int. J. Mol. Sci. 2021, 22(14), 7605;
Received: 7 June 2021 / Revised: 12 July 2021 / Accepted: 13 July 2021 / Published: 16 July 2021
(This article belongs to the Special Issue Pharmacological Strategies for Metabolic Diseases: New Evidence)
COVID-19 infection poses an important clinical therapeutic problem, especially in patients with coexistent diseases such as type 2 diabetes. Potential pathogenetic links between COVID-19 and diabetes include inflammation, effects on glucose homeostasis, haemoglobin deoxygenation, altered immune status and activation of the renin-angiotensin-aldosterone system (RAAS). Moreover, drugs often used in the clinical care of diabetes (dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, metformin and insulin) may influence the course of SARS-CoV-2 infection, so it is very important to verify their effectiveness and safety. This review summarises the new advances in diabetes therapy and COVID-19 and provides clinical recommendations that are essential for medical doctors and for patients suffering from type 2 diabetes. View Full-Text
Keywords: COVID-19; diabetes; therapy COVID-19; diabetes; therapy
Show Figures

Figure 1

MDPI and ACS Style

Bielka, W.; Przezak, A.; Pawlik, A. Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection. Int. J. Mol. Sci. 2021, 22, 7605.

AMA Style

Bielka W, Przezak A, Pawlik A. Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection. International Journal of Molecular Sciences. 2021; 22(14):7605.

Chicago/Turabian Style

Bielka, Weronika, Agnieszka Przezak, and Andrzej Pawlik. 2021. "Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection" International Journal of Molecular Sciences 22, no. 14: 7605.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop